Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
Published

Study: Psilocybin enhances therapy in patients with major depression

Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open-label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment-resistant depression, the researchers stated. Study results were published online Nov. 4, 2020, in JAMA Psychiatry.

Open source BibTeX RIS

Bibliographic context

Journal
The Brown University Psychopharmacology Update
Date
2021-01-06
Source
OpenAlex
DOI
10.1002/pu.30675
PubMed
Unavailable

Authors

Watch author

Topics and keywords

psilocybin DepressionAnxietyRandomized Controlled TrialTreatment-Resistant Depression Randomized Controlled Trial PsilocybinDepression (economics)MedicinePsychiatryAntidepressantMajor depressive disorderHallucinogenRandomized controlled trialPsychotherapistPsychologyAnxietyInternal medicineCognitionMacroeconomicsEconomicsPsychedelics and Drug StudiesDigital Mental Health InterventionsMental Health Research Topics

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Study: Psilocybin enhances therapy in patients with major depression2021-01-06

Related papers

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étudeThe Canadian Journal of Psychiatry · 2025-03-24P388. Open Label Psilocybin Administration in Severely Treatment Resistant DepressionBiological Psychiatry · 2022-04-27Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17Pilot study of psilocybin in patients with post-treatment lyme diseaseScientific Reports · 2026-02-24The Potential of Psilocybin Administration in Terminal Cancer PatientsOncology Times · 2019-06-27Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative ReviewJournal of Education Health and Sport · 2026-05-06Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive DisorderInternational Journal of Mental Health and Addiction · 2024-03-06Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trialBJPsych Open · 2023-06-30